

Opioid receptor stimulation does not affect cellular hypoxia-induced gene responses mediated by hypoxia-inducible factor 1 in cultured cell lines

SATOSHI TAKABUCHI^{1,2}, KIICHI HIROTA^{1,2}, SEIKO ODA^{1,2}, KENICHIRO NISHI^{1,3}, TOMOYUKI ODA^{1,4}, KOH SHINGU³, TAKEHIKO ADACHI¹, and KAZUHIKO FUKUDA²

¹Department of Anesthesia, The Tazuke Kofukai Medical Research Institute, Kitano Hospital, Osaka, Japan

²Department of Anesthesia, Kyoto University Hospital, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan

³Department of Anesthesiology, Kansai Medical University, Moriguchi, Osaka, Japan

⁴Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan

Abstract

Hypoxia induces a series of adaptive physiological responses including gene inductions. Hypoxia-inducible factor 1 (HIF-1) is a master transcription factor that regulates hypoxia-induced gene expression to maintain homeostasis in the living body. Opioids are potent analgesic agents that are widely used in clinical practice. Therefore, we investigated the effect of opioids on HIF-1 activity. SH-SY5Y human neuronal cells, which express opioid receptors intrinsically, were cultured under 1% or 20% O₂ conditions with or without treatment by DAGO, DPDPE, or U-50488, which are the selective agonists of μ -, δ -, and κ -opioid receptors, respectively. Expression of subunits of HIF-1, HIF-1 α , and HIF-1 β were examined by Western blot using specific antibodies. Expression of the HIF-1-dependent gene were investigated by reporter assay. None of the selective agonists of opioid receptors tested affected HIF-1 activation by hypoxia. Therefore, it is suggested that opioid receptor-mediated signals do not affect HIF-1-dependent cellular hypoxia-induced gene responses.

Key words Hypoxia · Hypoxia-inducible factor 1 (HIF-1) · Opioid · Guanine nucleotide-binding (G) protein-coupled receptor (GPCR) · SH-SY5Y

Hypoxia induces a series of adaptive physiological responses. The carotid body and neuroepithelial body are special sensor organs that detect O₂ concentration in the bloodstream. Today it is appreciated that all the cells have their own oxygen-sensing system to elicit gene expression mediated by transcription factors to accommodate hypoxia [1]. Hypoxia-inducible factor 1 (HIF-1) is a master transcription factor that regulates hypoxic gene expression and maintains cellular energy homeostasis. In addition to energy metabolism, activated HIF-

1 induces expression of its target genes required for angiogenesis, erythropoiesis, cell proliferation and viability, vascular remodeling, and vasomotor responses [1]. HIF-1 is a heterodimer consisting of HIF-1 α and HIF-1 β subunits that bind to the specific regulatory sequences known as the hypoxia response element (HRE). There is an established consensus that the biological activity of HIF-1 is mainly determined by the expression and transcriptional activity of the HIF-1 α subunit [2]. The HIF-1 α protein expression level is determined by an elaborate balance between protein synthesis and degradation as well as other intracellular proteins. The substrate (O₂) limitation induces HIF-1 α protein stabilization and transcriptional activation without induction of the mRNA [3].

HIF-1 activity is governed not only by O₂ tension but by various kinds of stimulation. We previously reported that insulin-like growth factor 1 (IGF-1) [4], prostaglandin E₂ (PGE₂) [5], the nitric oxide donor NOC18 [6], and stimulation of M1 or M3 subtypes of muscarinic acetylcholine receptor induce HIF-1 activation under normoxic conditions [7].

Because HIF-1 mediates physiological and pathophysiological responses with adaptive changes in target gene expression, it is intriguing to examine the effect of drugs used during the perioperative period on HIF-1 activity. We have reported the effect of the volatile anesthetic halothane [8], the intravenous anesthetic propofol [9], and local anesthetics [10] on hypoxia-induced HIF-1 activation in established cell lines. There have been no reports yet on the effect of opioids on the hypoxia-induced gene responses mediated by HIF-1 to the best of our knowledge. In this study we focus on opioids, which are potent analgesic agents and are widely used clinically for anesthesia and in pain clinics.

We examined the effect of opioids on the accumulation of HIF-1 α (Fig. 1, top panel). Phosphorylation of

Address correspondence to: K. Hirota

Received: November 30, 2004 / Accepted: April 4, 2005




Fig. 1. Effects of selective opioid agonists on hypoxia-inducible factor 1 (HIF-1 α) accumulation in SH-SY5Y cells. SH-SY5Y cells were treated with [D-Ala²,N-Me-Phe⁴,Gly⁵-ol]-enkephalin (DAGO), [D-Pen^{2,5}]-enkephalin (DPDPE), or (\pm)-*trans*-U-50488 methanesulfonate salt (U-50488) at 1 μ M (lane 2); or with 10 μ M DFX (lane 4) under 20% O₂ or 1% O₂ (lane 6) for 4h. They were then harvested for immunoblot assays using anti-HIF-1 α , anti-HIF-1 β , or anti- β -actin antibody. In lane 1 the cells underwent no treatment. We performed the experiment under almost the same conditions more than three times. The data presented are representative of the results of those experiments. The protein was quantified by densitometry assisted by the image analysis software NIH Image (version 1.62) and indicated as fold induction to each lane 1 after normalization to the value of expression for β -actin of the corresponding lane [6, 8, 11]




Fig. 2. Effects of DAGO in normoxia or hypoxia-induced HRE-dependent gene expression. SH-SY5Y cells were transfected with 50 ng of pRL-SV40 (control reporter encoding *Renilla* luciferase) and 200 ng of p2.1 (HRE-driven reporter encoding firefly luciferase) using Fugene 6 transfection reagent (Roche) [6, 7]. After 6h of incubation, cells were treated with DAGO under 20% or 1% (dark lines) O₂ for 18h and harvested for luciferase assays. The ratio of firefly/*Renilla* luciferase activity was determined and normalized to the value obtained from untreated cells under 20% O₂ to obtain the relative luciferase activity (RLA) [6, 7]

ERK1 and ERK2 were observed after treatment with [D-Ala²,N-Me-Phe⁴,Gly⁵-ol]-enkephalin (DAGO), [D-Pen^{2,5}]-enkephalin (DPDPE), or (\pm)-*trans*-U-50488 methanesulfonate salt (U-50488), indicating that SY5Y cells express μ , δ , and κ opioid receptor functionally (data not shown). SH-SY5Y cells express HIF-1 α under 20% O₂ condition (lane 1) without treatment with opioids; the expression increases in response to the iron chelator DFX (lane 3) and exposure to 1% O₂ atmosphere (lane 5), both of which are identified as strong HIF-1 α inducers [6, 8, 11]. In contrast, all of the selective agonists of opioid receptors used in this study had no effect of the accumulation of HIF-1 α under the above-mentioned conditions (lanes 2, 4, and 6). Expression of HIF-1 β was constant (Fig. 1, middle panel). The expression of β -actin was not affected by the treatments (bottom panel). Expression of the mRNA of HIF-1 α and HIF-1 β was not affected significantly (data not shown).

Next, we investigated the effects of opioids on HIF-1 activation using a reporter gene system (Fig. 2). SH-SY5Y cells were transfected with the reporter p2.1 containing HIF-1-dependent HREs and pSV40-RL encoding *Renilla* luciferase, incubated with or without DAGO, and then subjected to a reporter assay, which is the most sensitive assay for examining HIF-1 activation. Hypoxic treatment increased HRE-dependent gene expression about 60-fold. DAGO did not affect hypoxia-induced HRE-dependent gene expression or

expression under 20% O₂ conditions, suggesting that activation of μ -opioid receptor had no effect on HIF-1-dependent gene expression. This result is consistent with our unpublished observation that stimulation of the receptors did not affect HIF-1 activity using the Chinese hamster ovary (CHO)-derived established cell line CHO-1 stably exogenously expressing the μ -, δ -, or κ -opioid receptors.

Using SH-SY5Y human neuroblastoma cells, we demonstrated the null effect of opioid receptor stimulation on hypoxia-mediated gene expression mediated by the transcription factor HIF-1. Opioid receptor-mediated signals affect neither protein expression of HIF-1 nor gene expression tested by reporter gene assay under normoxic or hypoxic conditions. It is reported that opioid receptors constitute mono- and hetero-complexes with each other, and these new receptor complexes exhibit functional properties that are distinct from those of either receptor [12]. Moreover, opioid receptors (1) functionally and physically cross-talk with other guanine nucleotide-binding (G) protein-coupled receptors, such as β -adrenergic receptors, via multiple hierarchical mechanisms including heterodimerization of these receptors, (2) counterbalance functional opposing G protein signaling, and (3) interface at a downstream signal [13]. Further studies are to be performed especially in situations similar to clinical settings, such as evaluating the coexistence of opioid analgesics and catecholamines.

Opioids are widely used as analgesics in combination with general anesthetics or tranquilizers in various clinical settings. The receptors are expressed not only in neuronal cells but also immunocompetent cells. Because HIF-1 is a key molecule for the cells to adapt to hypoxic conditions, activation of HIF-1 may play an important protective role in critical organs. In fact, experiments using genetically modified mice clearly indicate a critical role for HIF-1 in organ protection against hypoxic insults. Taking into account evidence that the volatile anesthetic halothane [8] and the intravenous anesthetic propofol [9] inhibit HIF-1 activity, patient management under general anesthesia or in intensive care using opioid receptor ligands may have some advantage from this point of view. Further extensive studies are required to examine the effects of opioid analgesics used in the clinical setting, as each drug acts on multiple subtypes of receptors and sets up interactions among them.

Acknowledgments. We thank Dr. Gregg L. Semenza, Johns Hopkins University, for providing reporter plasmids. This study was supported by research grants from the Ministry of Science, Education, and Sport to T.A. and K.H.

References

1. Hirota K (2002) Hypoxia-inducible factor 1, a master transcription factor of cellular hypoxic gene expression. *J Anesth* 16:150–159
2. Wang GL, Jiang BH, Rue EA, Semenza GL (1995) Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O₂ tension. *Proc Natl Acad Sci USA* 92: 5510–5514
3. Semenza GL (2001) HIF-1, O₂, and the 3 PHDs: how animal cells signal hypoxia to the nucleus. *Cell* 107:1–3
4. Fukuda R, Hirota K, Fan F, Jung YD, Ellis LM, Semenza GL (2002) Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. *J Biol Chem* 277:38205–38211
5. Fukuda R, Kelly B, Semenza GL (2003) Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E₂ is mediated by hypoxia-inducible factor 1. *Cancer Res* 63:2330–2334
6. Kasuno K, Takabuchi S, Fukuda K, Kizaka-Kondoh S, Yodoi J, Adachi T, Semenza GL, Hirota K (2004) Nitric oxide induces hypoxia-inducible factor 1 activation that is dependent on MAPK and phosphatidylinositol 3-kinase signaling. *J Biol Chem* 279: 2550–2558
7. Hirota K, Fukuda R, Takabuchi S, Kizaka-Kondoh S, Adachi T, Fukuda K, Semenza GL (2004) Induction of hypoxia-inducible factor 1 activity by muscarinic acetylcholine receptor signaling. *J Biol Chem* 279:41521–41528
8. Itoh T, Namba T, Fukuda K, Semenza GL, Hirota K (2001) Reversible inhibition of hypoxia-inducible factor 1 activation by exposure of hypoxic cells to the volatile anesthetic halothane. *FEBS Lett* 509:225–229
9. Takabuchi S, Hirota K, Nishi K, Oda S, Oda T, Shingu T, Takabayashi A, Adachi T, Semenza GL, Fukuda K (2004) The intravenous anesthetic propofol inhibits hypoxia-inducible factor 1 activity in an oxygen tension-dependent manner. *FEBS Lett* 577:434–438
10. Nishi K, Hirota K, Takabuchi S, Oda S, Fukuda K, Adachi T, Shingu T (2005) The effect of local anesthetics on the cellular hypoxia-induced gene responses mediated by hypoxia-inducible factor 1. *J Anesth* 19:54–59
11. Hirota K, Semenza GL (2001) Rac1 activity is required for the activation of hypoxia-inducible factor 1. *J Biol Chem* 276:21166–21172
12. Jordan BA, Devi LA (1999) G-protein-coupled receptor heterodimerization modulates receptor function. *Nature* 399:697–700
13. Pepe S, van den Brink OW, Lakatta EG, Xiao RP (2004) Cross-talk of opioid peptide receptor and beta-adrenergic receptor signalling in the heart. *Cardiovasc Res* 63:414–422